Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation
]In today’s fast-evolving healthcare and pharmaceutical industries, precision and reliability are non-negotiable. From hospitals and research laboratories to biotech companies and pharmaceutical manuf
By Megan Liu, Digital Health Reporter
Prolapse describes structural descent caused by failure of regular anatomical support. Pelvic organ prolapse is an organ herniation into or beyond the vagina driven by weakness in the muscles, fascia
By Megan Liu, Digital Health Reporter
Calciphylaxis, also termed calcific uremic arteriolopathy, is uncommon yet catastrophic. Small and medium dermal arterioles mineralise and thrombose, tissue perfusion collapses, and exquisitely painfu
By Dr. Eleanor Vance, Regulatory Affairs Editor
Isopropyl alcohol (IPA) remains a critical solvent and intermediate in various industries, including healthcare, personal care, and electronics. Analyst estimates diverge on headline size, yet all sig
By Dr. Eleanor Vance, Regulatory Affairs Editor
A single figure can sway a submission or a clinical decision. When continuous data are grouped with unequal intervals, a simple count by bin exaggerates wide ranges and hides concentrated patterns. Th
By Priya Raghavan, Biotech & Markets Analyst
Huntington's disease remains without a cure in 2025. Clinical practice focuses on symptom control while a new wave of molecular programmes seeks to slow or halt neurodegeneration. The evidence base po
By Dr. Eleanor Vance, Regulatory Affairs Editor
A familiar antibiotic has crossed an ocean with an unfamiliar name. In April 2024 the U.S. Food and Drug Administration approved Pivya pivmecillinam for uncomplicated urinary tract infection in adult
By Dr. Eleanor Vance, Regulatory Affairs Editor
Testosterone replacement therapy is widely requested, yet appropriate use depends on accurate diagnosis. True androgen deficiency is a clinical and biochemical syndrome. Symptoms must align with repea
By Tom Okafor, Clinical Trials Correspondent
Five years after the acute waves of COVID-19, Long COVID has settled into public health planning as a common post-infectious condition with sustained clinical, economic and social effects. The term de
By Dr. Eleanor Vance, Regulatory Affairs Editor
Nitazenes are highly potent synthetic opioids from the benzimidazole family that now present a fast-moving threat in the United Kingdom and in other regions. The core scaffold places them apart from n
By Dr. Eleanor Vance, Regulatory Affairs Editor
Public attention to nicotinamide mononucleotide has grown quickly as evidence about NAD+ biology has entered mainstream discussion. Early animal data suggested broad benefits across metabolic and vasc
By Dr. Eleanor Vance, Regulatory Affairs Editor
Cellular ageing is not a single event but a convergence of gradual molecular failures that accumulate over time. The recognised hallmarks include telomere attrition, genomic instability from DNA damag
By Dr. Eleanor Vance, Regulatory Affairs Editor
Subscribe to our weekly pharmaceutical intelligence digest
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy